Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
11,181,416
-
Total 13F shares
-
26,264,313
-
Share change
-
+19,750
-
Total reported value
-
$69,861,906
-
Price per share
-
$2.66
-
Number of holders
-
34
-
Value change
-
-$1,368,220
-
Number of buys
-
11
-
Number of sells
-
15
Institutional Holders of Ikena Oncology, Inc. - Common Stock, $0.001 par value (IKNA) as of Q4 2022
As of 31 Dec 2022,
Ikena Oncology, Inc. - Common Stock, $0.001 par value (IKNA) was held by
34 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
26,264,313 shares.
The largest 10 holders included
Atlas Venture Life Science Advisors, LLC, FMR LLC, ORBIMED ADVISORS LLC, BVF INC/IL, Omega Fund Management, LLC, CITADEL ADVISORS LLC, CHI Advisors LLC, Verition Fund Management LLC, Artal Group S.A., and VANGUARD GROUP INC.
This page lists
34
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.